Literature DB >> 8293557

Viral infection and the pathogenesis of dilated cardiomyopathy.

T A Martino1, P Liu, M J Sole.   

Abstract

Long-term follow-up studies of patients with suspected viral myocarditis reveal progression to dilated cardiomyopathy (DCM) in a significant number of cases. Thus, an underlying viral etiology has been hypothesized in the pathogenesis of ongoing heart disease that leads to DCM. Recent application of molecular biology in clinical diagnosis has strengthened this hypothesis. By use of probe hybridization and polymerase chain reaction, enteroviral RNA has been detected in the myocardium of patients at all stages of the disease process: myocarditis, chronic heart disease, and DCM. Experimental murine models of enterovirus-induced heart disease provide a framework for examining the pathogenic mechanisms. Viral cytotoxicity, immunological responses, viral RNA persistence, and spasm of the coronary microvasculature are all implicated in the ongoing disease process. Abnormal cardiac function and heart failure are attributed to the pathological changes that occur.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8293557     DOI: 10.1161/01.res.74.2.182

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  50 in total

Review 1.  Influence of myocarditis on left ventricular function.

Authors:  K L Baughman
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

Review 2.  Cardiac myosin and the TH1/TH2 paradigm in autoimmune myocarditis.

Authors:  M W Cunningham
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 3.  Virus-receptor interactions of coxsackie B viruses and their putative influence on cardiotropism.

Authors:  Hans-Christoph Selinka; Antje Wolde; Martina Sauter; Reinhard Kandolf; Karin Klingel
Journal:  Med Microbiol Immunol       Date:  2003-08-14       Impact factor: 3.402

4.  Long-term follow-up of patients paragraph sign with acute myocarditis by magnetic paragraph sign resonance imaging.

Authors:  Anja Wagner; Jeanette Schulz-Menger; Rainer Dietz; Matthias G Friedrich
Journal:  MAGMA       Date:  2003-02       Impact factor: 2.310

5.  Progress in targeted delivery of siRNA to combat Coxsackievirus.

Authors:  Anju Gautam
Journal:  Protein Cell       Date:  2011-11       Impact factor: 14.870

6.  Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.

Authors:  Maowei Wang; Yan Yue; Chunsheng Dong; Xiaoyun Li; Wei Xu; Sidong Xiong
Journal:  Clin Vaccine Immunol       Date:  2013-09-11

7.  A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection.

Authors:  M Dan; J K Chantler
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  Coxsackievirus B3 infection and its mutation in Keshan disease.

Authors:  Li-Qun Ren; Xiang-Jun Li; Guang-Sheng Li; Zhi-Tao Zhao; Bo Sun; Fei Sun
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

9.  Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes.

Authors:  Thomas P Zwaka; Dimitar Manolov; Cüneyt Ozdemir; Nikolaus Marx; Ziya Kaya; Matthias Kochs; Martin Höher; Vinzenz Hombach; Jan Torzewski
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

10.  Chagas Cardiomyopathy in New Orleans and the Southeastern United States.

Authors:  Robert C Hsu; Joshua Burak; Sumit Tiwari; Chayan Chakraborti; Gary E Sander
Journal:  Ochsner J       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.